Soleno Therapeutics (United States)

Recent papers from Soleno Therapeutics (United States)

1. Discovery and Optimization of AMT‐676, a CDH17‐Targeting ADC for the Treatment of Advanced Gastrointestinal CancersAdvanced Science · 2026
2. ADCE-T02 – a Next Generation Antibody Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and TolerabilityMolecular Cancer Therapeutics · 2026
3. Abstract 6927: ADCE-T02 - A clinical stage antibody drug conjugate targeting tissue factor demonstrates strong efficacy in preclinical models of head and neck squamous cell carcinomaCancer Research · 2026
4. Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDSBlood · 2026
5. Hematopoietic stem cell transplantation using briquilimab (Anti-CD117 Antibody-Conditioning), immunosuppression and TCRαβ+ T-cell/CD19+ B-cell depleted haploidentical grafts in patients with fanconi anemia: An approach without irradiation, busulfan and calcineurin inhibitors.Blood · 2025
6. Preclinical efficacy of the muscarinic agonist ML-007 in psychosis models depends on both M1 and M4 receptorsNeuropsychopharmacology · 2025
7. Anti-KIT antibody, briquilimab, induces mast cell apoptosis and depletion in nonhuman primatesJournal of Allergy and Clinical Immunology · 2025
8. The burden of illness in Prader-Willi syndrome: a systematic literature reviewOrphanet Journal of Rare Diseases · 2025
9. Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed/Refractory MyelofibrosisBlood · 2024
10. Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory MyelofibrosisBlood · 2024
11. POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to RuxolitinibBlood · 2024
12. 7519 Withdrawal of DCCR (Diazoxide Choline) Extended-Release Tablets Worsens Hyperphagia and Increases Weight and BMI in a 16-week Double-blind, Placebo-controlled, Randomized Withdrawal Period in Patients with Prader Willi SyndromeJournal of the Endocrine Society · 2024
13. Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced or metastatic ovarian cancer: Results from a multi-center multi-country phase 1/2a expansion cohort.Journal of Clinical Oncology · 2024
14. Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced neuroendocrine cancers: Results from a multi-center multi-country phase 1/2a expansion cohort.Journal of Clinical Oncology · 2024
15. Behavioral changes in patients with Prader-Willi syndrome receiving diazoxide choline extended-release tablets compared to the PATH for PWS natural history studyJournal of Neurodevelopmental Disorders · 2024
16. Diazoxide choline extended‐release tablet in people with Prader‐Willi syndrome: results from long‐term open‐label studyENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2023
17. Pharmacokinetics and Pharmacodynamics of Burixafor Hydrobromide (GPC‐100), a Novel C‐X‐C Chemokine Receptor 4 Antagonist and Mobilizer of Hematopoietic Stem/Progenitor Cells, in Mice and Healthy SubjectsClinical Pharmacology in Drug Development · 2023
18. Body Mass Index, Obesity, and Mortality– Part INutrition Today · 2023
19. Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled TrialThe Journal of Clinical Endocrinology & Metabolism · 2023
20. Chromosomal Microarray Study in Prader-Willi SyndromeInternational Journal of Molecular Sciences · 2023